Second Tranche Of $91 Million Venture Round Will Help Advance Two Formulations Of Radius’ Osteoporosis Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Radius, which reverse-merged into a public company this past May, has advanced an injectable formulation of BA058 into Phase III, while it is preparing to move a transdermal version into Phase II.
You may also be interested in...
Financings Of The Fortnight Considers The Value Of Insider Participation In Biotech IPOs
Plus news on recent financings by Radius Health, Cempra, Ironwood and Acetylon.
Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing
Five new investors back the owner of anabolic bone therapy BA058, while a reverse merger paves the way to the public markets.